De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate. [PDF]
Adv TherGudesblatt M +14 more
europepmc +1 more source
Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. [PDF]
Adv Ther, 2019 Palte MJ +7 more
europepmc +1 more source
Transition from anti-CD20 therapies to fumarates as a treatment strategy: A multicenter, retrospective observational experience. [PDF]
Mult Scler J Exp Transl ClinVollmer BL +8 more
europepmc +1 more source
Efficacy and safety of disease-modifying oral drugs in treatment of relapsing-remitting multiple sclerosis: systematic review and network meta-analysis. [PDF]
Front ImmunolZhao Y +8 more
europepmc +1 more source
Dimethyl Fumarate vs. Monomethyl Fumarate: Unresolved Pharmacologic Issues. [PDF]
PharmaceuticsKopincova J, Bernatova I.
europepmc +1 more source
A Randomised, Double-Blind Study Comparing the Gastrointestinal Tolerability of Tegomil Fumarate Versus Dimethyl Fumarate in Healthy Volunteers. [PDF]
Neurol TherFonseca M +4 more
europepmc +1 more source
Severe Primary Central Sleep Apnea in a Patient with Multiple Sclerosis [PDF]
Fong, Susie X., Maller, Abigail
core
A Comparative Study of Clinical and Demographic Profiles of Multiple Sclerosis Patients in Two Regional Centers in Denmark and Romania. [PDF]
Neurol IntVrînceanu O +4 more
europepmc +1 more source